Senseonics Overview
Industry: Medical Devices
Sector: Healthcare
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense, Eversense XL, and Eversense E3 which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense, Eversense XL, and Eversense E3 which are impl Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Senseonics into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $12.6M (+157% YoY). Net loss was -$36.7M. R&D expense was $11.6M.
What changed
- Revenue +157% YoY to $12.6M.
Guidance / outlook
The Company expects this timing dynamic to normalize in the third and fourth quarters, with Europe still expected to represent approximately 20% of full-year revenue.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights
Headline from Yahoo Finance: Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights.
Senseonics Holdings Inc (SENS) (Q2 2026) Earnings Call Highlights: Revenue Soars 120% as ...
Headline from Yahoo Finance: Senseonics Holdings Inc (SENS) (Q2 2026) Earnings Call Highlights: Revenue Soars 120% as .
Senseonics Holdings Inc earnings missed by $0.02, revenue topped estimates
Headline from Investing.com Canada: Senseonics Holdings Inc earnings missed by $0.02, revenue topped estimates.
Earnings call transcript: Senseonics tops revenue forecasts in Q2 2026 By Investing.com
Headline from Investing.com Canada: Earnings call transcript: Senseonics tops revenue forecasts in Q2 2026 By Investing.com.
Senseonics Holdings Inc earnings missed by $0.02, revenue topped estimates
Headline from Investing.com: Senseonics Holdings Inc earnings missed by $0.02, revenue topped estimates.
Earnings call transcript: Senseonics tops revenue forecasts in Q2 2026
Headline from Investing.com: Earnings call transcript: Senseonics tops revenue forecasts in Q2 2026.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.